ADRX-0405 — Investigational Agent
Antibody-Drug Conjugate · Phase 1 · Adcendo / Adaris Therapeutics
Mechanism of Action
A STEAP1-directed antibody-drug conjugate that binds the six-transmembrane epithelial antigen of the prostate and delivers a topoisomerase inhibitor payload to STEAP1-expressing tumor cells.
Investigational Indications
- Metastatic castration-resistant prostate cancer
- STEAP1-expressing solid tumors